J. Odendaal, Fiona L Mackie, Sofia Tosounidou, Swati Ghosh, Ellen Knox
{"title":"妊娠期肉样瘤病","authors":"J. Odendaal, Fiona L Mackie, Sofia Tosounidou, Swati Ghosh, Ellen Knox","doi":"10.1111/tog.12917","DOIUrl":null,"url":null,"abstract":"\n\n\nSarcoidosis is an uncommon multi‐system disorder characterised by the presence of non‐caseating granulomas. It has a peak incidence between the ages of 20–40 years old.\n\nThe pathogenesis of sarcoidosis is uncertain; however, it is known to be associated with an exaggerated T helper 1 (TH1) immune response leading to systemic inflammation and granuloma formation.\n\nSuppression in TH1 responses in pregnancy leads to disease remission in the majority of pregnancies. Nevertheless, the potential for decompensation in a subgroup remains, and consideration should be given to the pre‐pregnancy state.\n\nSarcoidosis is associated with increased risk of maternal‐fetal morbidity, including growth restriction and pre‐eclampsia. Clinical management should focus on medication optimisation and mitigation of this increased risk.\n\n\n\n\nTo understand the clinical features, pathogenesis and diagnosis of sarcoidosis.\n\nTo understand the effect of pregnancy on sarcoidosis.\n\nTo understand the effect of sarcoidosis on pregnancy and the related obstetric outcomes.\n\nTo understand the management of sarcoidosis in pregnancy.\n\n\n\n\nThere can be difficulties in appropriate management of medical disorders, such as sarcoidosis, with a limited obstetric evidence base.\n\nThere are challenges in decision‐making regarding continuation of pregnancy in severe disease with an uncertain evidence base.\n\n","PeriodicalId":509656,"journal":{"name":"The Obstetrician & Gynaecologist","volume":"154 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sarcoidosis in pregnancy\",\"authors\":\"J. Odendaal, Fiona L Mackie, Sofia Tosounidou, Swati Ghosh, Ellen Knox\",\"doi\":\"10.1111/tog.12917\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\n\\nSarcoidosis is an uncommon multi‐system disorder characterised by the presence of non‐caseating granulomas. It has a peak incidence between the ages of 20–40 years old.\\n\\nThe pathogenesis of sarcoidosis is uncertain; however, it is known to be associated with an exaggerated T helper 1 (TH1) immune response leading to systemic inflammation and granuloma formation.\\n\\nSuppression in TH1 responses in pregnancy leads to disease remission in the majority of pregnancies. Nevertheless, the potential for decompensation in a subgroup remains, and consideration should be given to the pre‐pregnancy state.\\n\\nSarcoidosis is associated with increased risk of maternal‐fetal morbidity, including growth restriction and pre‐eclampsia. Clinical management should focus on medication optimisation and mitigation of this increased risk.\\n\\n\\n\\n\\nTo understand the clinical features, pathogenesis and diagnosis of sarcoidosis.\\n\\nTo understand the effect of pregnancy on sarcoidosis.\\n\\nTo understand the effect of sarcoidosis on pregnancy and the related obstetric outcomes.\\n\\nTo understand the management of sarcoidosis in pregnancy.\\n\\n\\n\\n\\nThere can be difficulties in appropriate management of medical disorders, such as sarcoidosis, with a limited obstetric evidence base.\\n\\nThere are challenges in decision‐making regarding continuation of pregnancy in severe disease with an uncertain evidence base.\\n\\n\",\"PeriodicalId\":509656,\"journal\":{\"name\":\"The Obstetrician & Gynaecologist\",\"volume\":\"154 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Obstetrician & Gynaecologist\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1111/tog.12917\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Obstetrician & Gynaecologist","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/tog.12917","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
肉样瘤病是一种不常见的多系统疾病,以出现非酪氨酸肉芽肿为特征。肉样瘤病的发病机理尚不明确,但已知与 T 辅助细胞 1(TH1)免疫反应过强导致全身炎症和肉芽肿形成有关。肉样瘤病与母胎发病风险增加有关,包括生长受限和先兆子痫。了解肉样瘤病的临床特征、发病机制和诊断,了解妊娠对肉样瘤病的影响,了解肉样瘤病对妊娠的影响及相关的产科结果,了解妊娠期肉样瘤病的管理。
Sarcoidosis is an uncommon multi‐system disorder characterised by the presence of non‐caseating granulomas. It has a peak incidence between the ages of 20–40 years old.
The pathogenesis of sarcoidosis is uncertain; however, it is known to be associated with an exaggerated T helper 1 (TH1) immune response leading to systemic inflammation and granuloma formation.
Suppression in TH1 responses in pregnancy leads to disease remission in the majority of pregnancies. Nevertheless, the potential for decompensation in a subgroup remains, and consideration should be given to the pre‐pregnancy state.
Sarcoidosis is associated with increased risk of maternal‐fetal morbidity, including growth restriction and pre‐eclampsia. Clinical management should focus on medication optimisation and mitigation of this increased risk.
To understand the clinical features, pathogenesis and diagnosis of sarcoidosis.
To understand the effect of pregnancy on sarcoidosis.
To understand the effect of sarcoidosis on pregnancy and the related obstetric outcomes.
To understand the management of sarcoidosis in pregnancy.
There can be difficulties in appropriate management of medical disorders, such as sarcoidosis, with a limited obstetric evidence base.
There are challenges in decision‐making regarding continuation of pregnancy in severe disease with an uncertain evidence base.